NAMs Network

Pro Anima > NAMs Network

This network aims to bring together all individuals interested in the field of alternative methods to animals for scientific purposes (in vitro, in silico, etc.): researchers, engineers, industrialists, regulators and institutions. The idea is to create a broad network to foster dialogue between key players, share important information, generate new collaborations and gather solid scientific data to validate and promote alternative methods to animal experimentation.

Main objectives of the network

Building links and dialogue across private, public and regulatory sectors
Gather expertise, essential information and data (strengthening scientific evidence)
Promoting new collaborations and events, as well as funding opportunities and resource mobilization
Training and educating the scientific community on NAMs

Tools

A Linkedin group

With more than 430 members (from industry, biotech, academia, etc, and different regions of the world), it was launched for daily / regular interactions and information sharing ; moderated by Pro Anima.

Monthly Live Talks

This year, we are setting up a series of Live talks on NAMs. The idea is to take 1h every month to freely discuss on a burning topic related to NAMs with the members of the network and external guests.

If you want to contribute to the framing of the next sessions, kindly answer the poll below.

Answer the poll

Session 1: Introducing the NAMs Network and the Live Talks Series — February 4th, 12 – 1pm (CET)

Watch the replay

Session 2: Where are we with NAMs, and why? – A US perspective, March 5th 4pm-5pm (CET)

Aim: Discussing the current momentum in the US with a focus on the role of NAMs to address the problem of translatability — starting by defining the magnitude of the issue, identifying key challenges, and then discussing perceived solutions and remaining risks across science, regulation, and policy.

Co-host and facilitator: Dr. Zaher Nahle, CHE & Ivyctory Solutions
Guest: Dr Daniel Levner, Co-Founder & CTO at Emulate Inc.

Q&A: you can submit questions ahead on the registration form.

In this session, we will be discussing the current momentum in the US with a focus on the role of NAMs to address the problem of translatability — starting by defining the magnitude of the issue, identifying key challenges, and then discussing perceived solutions and remaining risks across science, regulation, and policy.

Co-host and facilitator: Dr. Zaher Nahle, CHE & Ivyctory Solutions

Zaher Nahle is an interdisciplinary executive scientist with senior leadership experience across biomedical research, academia, and public policy, including roles as Chief Scientific Officer, Vice President for Research, and CEO at major U.S. medical foundations. A former faculty member at Vanderbilt and Cornell, he has published extensively in leading journals and pioneered high-throughput technologies such as gene microarrays. He currently serves as Senior Scientific Advisor to the Center for a Humane Economy and Animal Wellness Action and is the founder of the IVYCTORY Group.

Guest: Dr Daniel Levner, Co-Founder & CTO at Emulate Inc.

Daniel is the Chief Technology Officer at Emulate. A serial deep-tech entrepreneur, Levner co-founded Emulate and brings to it extensive experience in biological and engineering technology development and commercialization. Levner joined the Emulate founding team during his role as a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University. There, he led the advanced engineering team responsible for developing the Emulate Organ-Chip platform and played a key leadership role formulating innovative approaches for bridging biologists, engineers and business stakeholders. Daniel received his PhD in electrical engineering from Stanford University as well as an MS in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 70 issued and pending US patents. Q&A: you can submit questions ahead on the registration form below.